The Effect Of Serotonın Reuptake Inhıbıtor Use On Restless Legs Syndrome In Chıldren

Yıl 2025, Cilt: 12 Sayı: 1, 110 - 116, 26.03.2025

Derya Yavuz Demiray , Seda Aybüke Sarı , Mehmet Erdem

https://doi.org/10.34087/cbusbed.1627593

Öz

Objective: This research intends to investigate the relationship between selective serotonin reuptake inhibitors (SSRIs) and the occurrence rate of Restless Legs Syndrome (RLS) among pediatric and adolescent populations diagnosed with depression and/or anxiety disorders.
Materials and Methods: This retrospective study examined patients between the ages of 10 and 17 who had been prescribed one of the following selective serotonin reuptake inhibitors (SSRIs): fluoxetine, sertraline, or escitalopram. Exclusion criteria included patients with iron deficiency anemia, diabetes mellitus, renal disorders, spinal cord conditions, those receiving antihistaminic or antipsychotic medications, and individuals with other psychiatric or neurological disorders. The study meticulously recorded demographic information, medical histories, ferritin levels, vitamin B12 levels, and a family history of restless legs syndrome (RLS). Furthermore, the severity of RLS was evaluated using a specific scale for patients diagnosed with the condition.
Results: Among the 40 children analyzed, 10% developed RLS. The results indicated a potential link between SSRI use and the onset of RLS symptoms. No significant relationship was found between RLS and hemoglobin, ferritin, or vitamin B12 levels. Half of the RLS patients had a family history of RLS.
Conclusion: The results indicate a possible association between the administration of SSRIs and the emergence of RLS in pediatric and adolescent populations. It is advisable to conduct additional studies with an expanded sample size.

Anahtar Kelimeler

Restless Legs Syndrome, Serotonin Reuptake Inhibitors, Children, Depression, Anxiety Disorders

Etik Beyan

The ethical approval was obtained from the Mustafa Kemal University Local Ethics Committee (2024.07.09/19). The study was performed by the principles stated in the Declaration of Helsinki.

Destekleyen Kurum

The authors did not receive any financial support for the research or authorship of this study

ÇOCUKLARDA SEROTONİN GERİ ALIM İNHİBİTÖRÜ KULLANIMININ HUZURSUZ BACAK SENDROMU ÜZERİNE ETKİSİ

Öz

Amaç: Bu araştırma, seçici serotonin geri alım inhibitörleri (SSRI'lar) ile depresyon ve/veya anksiyete bozuklukları tanısı alan çocuk ve ergen popülasyonlarında Huzursuz Bacak Sendromu (HBS) görülme oranı arasındaki ilişkiyi incelemeyi amaçlamaktadır.

Gereç ve Yöntemler: Bu retrospektif çalışmada, fluoksetin, sertralin veya essitalopram gibi seçici serotonin geri alım inhibitörlerinden (SSRI'lar) birini kullanmış 10-17 yaş arası hastalar incelenmiştir. Dışlama kriterleri arasında demir eksikliği anemisi, diyabet, böbrek hastalıkları, omurilik rahatsızlıkları, antihistaminik veya antipsikotik ilaç kullananlar ve diğer psikiyatrik ya da nörolojik bozukluklara sahip hastalar yer almıştır. Çalışmada, demografik bilgiler, tıbbi geçmiş, ferritin seviyeleri, vitamin B12 seviyeleri ve ailede huzursuz bacak sendromu (HBS) öyküsü kaydedilmiştir. Ayrıca, HBS tanısı konulan hastaların durumunun şiddeti HBS şiddet ölçeği ile değerlendirilmiştir.

Bulgular: Analiz edilen 40 çocuk arasında %10’unda HBS gelişmiştir. Sonuçlar, SSRI kullanımının HBS semptomlarının ortaya çıkışıyla potansiyel bir bağlantısı olabileceğini göstermiştir. HBS ile hemoglobin, ferritin veya vitamin B12 seviyeleri arasında anlamlı bir ilişki bulunmamıştır. HBS tanısı alan hastaların yarısında HBS aile öyküsü tespit edilmiştir.

Sonuç: Sonuçlar, SSRI kullanımının çocuk ve ergen popülasyonlarında HBS gelişimi ile olası bir ilişkiyi işaret etmektedir. Daha geniş bir örneklem büyüklüğüyle ek çalışmalar yapılması tavsiye edilmektedir.

Anahtar Kelimeler

Huzursuz bacak sendromu, çocuklar, serotonin gerialım inhibitörleri, depresyon, anksiyete bozuklukları

Kaynakça

• 1-Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol. 2001;18(2):128-47.
• 2-Benbir G, Guilleminault C. Pramipexole: a new use for an old drug - the potential use of pramipexole in the treatment of restless legs syndrome. Neuropsychiatr Dis Treat. 2006 ;2(4):393-405.
• 3-Walters AS. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord. 1995 ;10(5):634-42.
• 4-Picchietti DL, Bruni O, et al. Pediatric restless legs syndrome diagnostic criteria: an update by the International Restless Legs Syndrome Study Group. Sleep Med 2013;14(12):1253–9
• 5-Picchietti D, Winkelman JW. Restless legs syndrome, periodic limb movements in sleep, and depression. Sleep. 2005 ;28(7):891-8.
• 6-Picchietti D, Allen RP, et al. Restless legs syndrome: prevalence and impact in children and adolescents–thePeds REST study. Pediatrics 2007;120(2): 253–66.
• 7-Picchietti DL, Stevens HE. Early manifestations of restless legs syndrome in childhood and adolescence. Sleep Med. 2008;9(7):770-81.
• 8- Pagel JF, Forister N, Kwiatkowki C. Adolescent sleep disturbance and school performance: the confounding variable of socioeconomics. J Clin Sleep Med. 2007;3:19–2
• 9-Cole M, Simakajornboon N. Sleep-related movement disorders in children: recent updates. World J Pediatr. 2024 Nov 28.
• 10-Rottach KG, Schaner BM, et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res. 2008; 43:70 –5.
• 11-Brown LK, Dedrick DL, Doggett JW, Guido PS. Antidepressant medication use and restless legs syndrome in patients presenting with insomnia. SleepMed. 2005; 6:443 –50.
• 12-Dimmitt SB, Riley GJ. Selective serotonin receptor uptake inhibitors can reduce restless legs symptoms. Arch Intern Med. 2000;160:712.
• 13-Bailey AL, Makela EH, Asberg K. Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor Use as a Predictor of a Diagnosis of Restless Legs Syndrome. J Psychiatr Pract. 2016; 22(4):263-9.
• 14-Earley CJ, Connor J, et al. Altered brain iron homeostasis and dopaminergic function in restless legs syndrome (Willis-Ekbom disease). Sleep Med 2014;15(11):1288–301.
• 15-Silvestri R, DelRosso LM. Pediatric Restless Legs Syndrome. Sleep Med Clin. 2021;16(2):305-314.
• 16-DelRosso L, Bruni O. Treatment of pediatric restless legs syndrome. Adv Pharmacol 2019;84:237–53.
• 17-DelRosso LM, Mogavero MP, Baroni A, Bruni O, Ferri R. Restless Legs Syndrome in Children and Adolescents. Child Adolesc Psychiatr Clin N Am. 2021 ;30(1):143-157.
• 18-Kwatra V, Khan MA, Quadri SA, Cook TS. Differential Diagnosis and Treatment of Restless Legs Syndrome: A Literature Review. Cureus. 2018; 13;10(9):e3297.
• 19- Allen RP, Picchietti DL, et al; International Restless Legs Syndrome Study Group (IRLSSG). Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med. 2018 Jan;41:27-44.
• 20- Allen RP, Auerbach S, Bahrain H, Auerbach M, Earley CJ. The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. Am J Hematol. 2013 Apr;88(4):261-4.
• 21-Ferré S, García-Borreguero D, Allen RP, Earley CJ. New insights into the neurobiology of restless legs syndrome. Neuroscientist. 2019;25:113–25.
• 22-Picchietti MA, Picchietti DL. Advances in pediatric restless legs syndrome: Iron, genetics, diagnosis and treatment. Sleep Med. 2010;11(7):643-51.
• 23-Rolling, J., Rabot, J., et al. Nightmares and Sleep Disturbances in Children with PTSD: A Polysomnographic and Actigraphy Approach Evaluation. Journal of Clinical Medicine,2023; 12(20), 6570.
• 24- Baird T, McLeay S, et al. PTSD Initiative. Sleep Disturbances in Australian Vietnam Veterans With and Without Posttraumatic Stress Disorder. J Clin Sleep Med. 2018;15;14(5):745-752.
• 25- Kallweit U, Werth E, et al. Psychiatric Comorbidities in Restless Legs Syndrome. J Neuropsychiatry Clin Neurosci. 2016 ;28(3):239-42.
• 26- Jhoo JH, Yoon IY, et al. Availability of brainserotonintransporters in patients with restless legs syndrome. Neurology. 2010;74:513 –8.